Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Minako Nagai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2102-1276; OpenAlex author ID A5056127996. Sources: OpenAlex.

Their work

Papers
48 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
144
Papers, trials and grants by year

2015: 9 papers · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper · 2019: 5 papers · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: 9 papers · 2024: 6 papers · 2025: 3 papers · 2026: 3 papers

Papers 48

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  3. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Co-author DOI 10.1111/den.70229↗
  4. Role of radiotherapy in surgical approaches to pancreatic cancer treatment: A narrative review. First author DOI 10.1002/ags3.70012↗
  5. An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-025-02260-w↗
  6. Endoscopic biliary drainage with multi-hole self-expandable metallic stent during neoadjuvant chemoradiotherapy in pancreatic cancer. Co-author DOI 10.4253/wjge.v17.i11.111107↗
  7. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement. Co-author DOI 10.1002/ags3.12726↗
  8. Prognostic significance of creatine kinase in resected pancreatic cancer. Co-author DOI 10.1002/jhbp.12081↗
  9. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Co-author DOI 10.1016/j.pan.2024.07.013↗
  10. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.08.003↗
  11. Clinical significance and therapeutic implication of CD200 in pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.10.007↗
  12. Critical Role of Preoperative Hyperglycemia in Association with GFAT-1 Expression in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15985-4↗
  13. Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12629↗
  14. Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12655↗
  15. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Co-author DOI 10.1002/jhbp.1303↗
  16. Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2023.06.001↗
  17. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  18. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic du… First author DOI 10.1016/j.pan.2023.10.014↗
  19. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  20. Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcomes in Patients with Pancreatic Cancer. Co-author DOI 10.1097/xcs.0000000000000808↗
  21. Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report. Co-author DOI 10.1186/s40792-023-01720-w↗
  22. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Co-author DOI 10.1007/s10147-022-02131-x↗
  23. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  24. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33284↗
  25. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12325-021-01819-2↗
  26. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Co-author DOI 10.1016/j.pan.2021.01.013↗
  27. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗
  28. Application of liquid biopsy for surgical management of pancreatic cancer. Co-author DOI 10.1002/ags3.12317↗
  29. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-018-4791-7↗
  30. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… Co-author DOI 10.1007/s00268-018-4820-6↗
  31. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.05.461↗
  32. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  33. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  34. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-018-1709-7↗
  35. Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Recl… Co-author DOI 10.1007/s00268-017-4077-5↗
  36. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  37. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  38. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  39. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2015.10.034↗
  40. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. Co-author DOI 10.1002/jhbp.258↗
  41. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Co-author DOI 10.1007/s00268-015-3205-3↗
  42. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1304-0↗
  43. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  44. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  45. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  46. Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000395↗
  47. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. Co-author DOI 10.1186/s13046-015-0144-7↗
  48. Clinical significance of CD155 expression in human pancreatic cancer. Co-author PMID 25862891↗

Closest collaborators

The 25 strongest of 144 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 44 shared papers, 2015–2026 · strength 5.69
  2. Kota Nakamura · 21 shared papers, 2018–2025 · strength 3.49
  3. Satoshi Yasuda · 19 shared papers, 2015–2026 · strength 3.45
  4. Taichi Terai · 18 shared papers, 2021–2025 · strength 3.29
  5. Yuichiro Kohara · 13 shared papers, 2023–2025 · strength 2.60
  6. Satoshi Nishiwada · 24 shared papers, 2015–2025 · strength 2.37
  7. Takahiro Akahori · 22 shared papers, 2015–2024 · strength 1.71
  8. Kenji Nakagawa · 11 shared papers, 2018–2023 · strength 1.25
  9. Sohei Satoi · 13 shared papers, 2015–2026 · strength 1.14
  10. Naoya Ikeda · 10 shared papers, 2015–2021 · strength 0.81
  11. Ippei Matsumoto · 8 shared papers, 2015–2026 · strength 0.78
  12. Shoichi Kinoshita · 13 shared papers, 2015–2024 · strength 0.76
  13. Toshihiro Tanaka · 8 shared papers, 2015–2025 · strength 0.72
  14. Kenichiro Uemura · 7 shared papers, 2015–2026 · strength 0.67
  15. Michiaki Unno · 7 shared papers, 2015–2026 · strength 0.67
  16. Tadataka Takagi · 5 shared papers, 2019–2023 · strength 0.63
  17. Yoshiyuki Nakajima · 13 shared papers, 2015–2016 · strength 0.61
  18. Kimihiko Kichikawa · 9 shared papers, 2015–2019 · strength 0.58
  19. Tomohisa Yamamoto · 7 shared papers, 2015–2023 · strength 0.51
  20. Hiroaki Yanagimoto · 9 shared papers, 2015–2019 · strength 0.49
  21. Tsutomu Fujii · 3 shared papers, 2023–2026 · strength 0.48
  22. So Yamaki · 6 shared papers, 2015–2023 · strength 0.47
  23. Koh Kitagawa · 2 shared papers, 2025–2026 · strength 0.44
  24. Daisuke Hashimoto · 3 shared papers, 2021–2026 · strength 0.42
  25. Jin Peng He · 3 shared papers, 2022–2023 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.